Skip to search formSkip to main contentSkip to account menu

MGN1703

Known as: TLR9 Agonist MGN1703 
A synthetic oligonucleotide based on a proprietary double stem-loop immunomodulator design with potential immunostimulating activity. TLR9 agonist… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

DNA

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Combination of TLR9 agonist lefitolimod/MGN1703 with checkpoint inhibitors for cancer immunotherapy.
634Background: TLR9 agonists are potent activators of the immune system via induction of cellular and humoral responses… 
2017
2017
Toll-Like Receptor Agonists: Can They Exact a Toll on Human Immunodeficiency Virus Persistence?
In this issue of Clinical Infectious Diseases, Vibholm et al report on the first clinical trial of treatment with MGN1703… 
2017
2017
TLR9 agonist lefitolimod to improve antitumor effect of checkpoint inhibitors in vivo.
e14625Background: TLR9 agonists are potent activators of the immune system via induction of cellular and humoral responses… 
Review
2015
Review
2015
Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival.
680 Background: Patients with mCRC and disease control after induction with first-line chemotherapy +/- bevacizumab were included… 
Review
2015
Review
2015
A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703.
3049 Background: The double-blind placebo-controlled phase 2 IMPACT trial aimed to assess the clinical efficacy, safety, and… 
2015
2015
Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study
Meeting abstracts MGN1703, a potent immunomodulatory Toll-like receptor 9 (TLR-9) agonist, was compared to placebo in the… 
Review
2013
Review
2013
O-0012UPDATED RESULTS OF THE RANDOMIZED PHASE 2 IMPACT TRIAL: MAINTENANCE WITH TLR-9 AGONIST MGN1703 VS PLACEBO IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA (MCRC)
Background: The PRIME study reported significantly improved progression-free survival (PFS) and overall survival (OS) with… 
2012
2012
A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcinoma: The IMPACT study.
e14152 Background: Based on promising data from a phase 1 study of MGN1703 in patients with metastatic solid tumors including… 
2011
2011
Preliminary results of an ongoing phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line induction therapy…
618 Background: MGN1703 is a synthetic DNA-based immunomodulator, which acts as an agonist of toll-like receptor 9. The… 
2009
2009
MGN1703, a Novel TLR9-Agonist - Results of a Phase 1 Clinical Trial in Patients with Metastatic Malignancies.
Abstract 4730 Background The DNA-based immunomodulator MGN1703 stimulates the innate and cellular immune system mainly via the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)